As clinical trials grow increasingly complex, the need for smarter, faster, and more efficient data processes and analysis is in demand. Artificial intelligence (AI) emerges as a powerful tool, especially in programming and data management. For clinical trial professionals, AI offers the promise of streamlining workflows, improving data quality, and reducing time to database lock.
The evolving role of AI in clinical data programming
AI is not replacing clinical programmers; it’s augmenting them. AI should be considered a tool to use within clinical trials, just as EDC and SAS are commonly used tools. Automation tools driven by machine learning can now handle routine, rules-based programming tasks such as edit check generation, derivation logic, and data transformation. This allows programmers to focus on more strategic activities like validating statistical code or optimizing data pipelines. AI needs the expertise of our clinical trial professionals.
Natural Language Processing (NLP) is also making great progress. For instance, NLP can interpret free-text protocol documents to auto-generate specifications, electronic case report form (eCRF) templates, or even suggest initial SDTM mappings, significantly reducing manual effort.
AI in data cleaning and quality oversight
Traditionally, data cleaning has been labor-intensive, with data managers manually reviewing queries, data listings, and edit checks across multiple data sources and systems. AI tools can now proactively flag anomalies or data trends that human review might miss, such as unexpected patterns in lab values, inconsistencies across visits, or possible fraudulent data across participants and sites.
Predictive models can help identify study participants at high risk of dropout or noncompliance, enabling earlier intervention. This not only improves data completeness but also enhances trial efficiency and participant retention. The effort and cost of replacing clinical trial participants is significant and felt across all stakeholders. Improving the patient’s experience would be a significant way to save time, money, and accelerating progress.
AI in statistical programming: From code automation to advanced insights
Statistical programming is central to clinical trial analysis from producing tables, listings, and figures (TLFs) to preparing submission-ready datasets. Traditionally reliant on manual coding in SAS or R, this work is now gaining speed, consistency, and quality through AI augmentation.
Where AI adds value in statistical programming
- Automated code generation: AI models trained on historical programming logic can produce initial SAS macros or R scripts for common TLFs and dataset derivations. These drafts accelerate development by up to 40–60%, freeing programmers and biostatisticians to focus on complex analyses and interpretation.
- Code review and validation: AI-assisted tools can scan code for logic errors, inefficiencies, redundant steps, and deviations from programming standards. Acting as a “second reviewer,” they flag potential issues early and suggest optimizations.
- Dynamic statistical modeling: AI algorithms can rapidly explore large trial datasets to detect subgroup effects, anomalies, or emerging trends. When guided by statistical oversight, these insights can refine analysis plans and support adaptive trial decisions.
The aim is not to replace human judgment, but to boost productivity, reproducibility, and the speed of insight generation, without compromising scientific rigor.
AI in biostatistics: Powering smarter, more adaptive clinical trials
Biostatistics remains the foundation of evidence generation in clinical trials, providing the methodological rigor to transform raw data into reliable conclusions. In the context of AI, biostatisticians play a dual role: safeguarding scientific validity while leveraging new computational tools to enhance insight generation. This requires a careful balance between deep domain knowledge and technical proficiency in emerging AI-driven methodologies. From applying knowledge graphs (KGs) to map complex biomedical relationships, to developing predictive models that anticipate trial outcomes, biostatistics is evolving into a more dynamic and interconnected discipline.
Where AI adds value in biostatistics
- Balanced expertise: Integrating statistical theory with AI/ML techniques to ensure robust, interpretable results.
- Knowledge graph applications: Using KGs to uncover hidden relationships between biomarkers, treatments, and outcomes, supporting hypothesis generation and trial design.
- Early prediction tools: Building predictive models for recruitment success, dropout risk, and endpoint achievement.
- Segmentation and personalization: Identifying patient subgroups most likely to benefit from a therapy, improving trial efficiency and precision medicine strategies.
- Support for registrational trials: Leveraging AI to optimize trial design, stratify patient populations, and run simulations that ensure the study is powered and structured for regulatory success.
Regulatory readiness and caution
Despite its promise, AI must be implemented thoughtfully. Regulatory agencies like the FDA are increasingly open to the use of advanced technologies but expect transparency, traceability, and validation. AI-based tools must be auditable and explainable, especially when used in clinical data workflows that feed into regulatory submissions.
What’s next?
As AI becomes more embedded in clinical trial ecosystems, we can expect increased integration with EDC systems, CDISC standards, and statistical programming tools. The goal isn’t to eliminate human oversight but to enhance it, allowing clinical data professionals to make faster, better-informed decisions.
Final takeaways
AI is reshaping programming and data management in clinical trials. For clinical trial professionals, now is the time to become familiar with these tools, understand their capabilities and limitations, and engage with cross-functional teams to ensure responsible and impactful implementation. Ultimately our goal is to shorten drug development timelines and improve patient outcomes. With AI, we can be part of the solution to provide improved treatments for patients.
Interested in learning more?
Join Steven Thacker, Sheree King, Kunal Sanghavi, and Juan Pablo Garcia Martinez for their upcoming webinar, “How AI Enhances Biometrics Services: Streamlining Data Management and Improving Statistical Accuracy in Clinical Trials” on Thursday, August 28 at 10 am ET:
